VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Jan. 4, 2005) - Wex Phamaceuticals Inc. (TSX:WXI) is pleased to announce that it has successfully completed the enrollment and dosing of patients during the month December for the ongoing phase IIa opioid dependence study with Tetrodin(TM) (Wex’s proprietary formulation of Tetrodotoxin-TTX). This randomized, double-blind, placebo-controlled study evaluates the safety and efficacy of Tetrodin in decreasing the severity of withdrawal symptoms in opiate-dependent subjects who are receiving methadone.
